Home/Filings/4/0001209191-21-026867
4//SEC Filing

Janda Kim 4

Accession 0001209191-21-026867

CIK 0000850261other

Filed

Apr 14, 8:00 PM ET

Accepted

Apr 15, 6:43 PM ET

Size

9.0 KB

Accession

0001209191-21-026867

Insider Transaction Report

Form 4
Period: 2021-04-12
Janda Kim
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2021-04-12$3.50/sh+1,900$6,6504,900 total
  • Exercise/Conversion

    Non-qualified stock option

    2021-04-121,9000 total
    Exercise: $3.50From: 2012-04-15Exp: 2021-04-15Common Stock (1,900 underlying)
  • Sale

    Common Stock

    2021-04-12$6.97/sh1,900$13,2513,000 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 22, 2021.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.84 to $7.29, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.

Issuer

Sorrento Therapeutics, Inc.

CIK 0000850261

Entity typeother

Related Parties

1
  • filerCIK 0001518466

Filing Metadata

Form type
4
Filed
Apr 14, 8:00 PM ET
Accepted
Apr 15, 6:43 PM ET
Size
9.0 KB